Claims for Patent: 8,703,787

Summary for Patent: 8,703,787

Title:	Methods of using ALK inhibitors
Abstract:	The invention provides methods for using compounds of Formula (I) for treating an EML4-ALK+ mediated condition such as EML4-ALK+ non-small cell lung cancer, and optionally resistant to crizotinib; wherein R1, R2, R3, R4, R5 and R6 are as defined above.
Inventor(s):	Nanxin Li, Jennifer Leslie Harris, Peter McNamara, Fangxian Sun
Assignee:	Novartis AG
Application Number:	US13/981,046
Patent Claims:	1. A method for treating EML4-ALK+ mediated non-small cell lung cancer that is optionally resistant to crizotinib, comprising administering to a cell or subject a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein R1 is halo; R2 is H; or wherein R1 and R2 together with the carbon atoms to which they are attached form a 5-6 membered heteroaryl comprising 1-2 heteroatoms selected from N, O and S; R3 is SO2R7 wherein R7 is C1-6 alkyl; R4 is C1-6 alkoxy; R5 is piperidinyl optionally substituted with C1-6 alkyl; R6 is C1-6 alkyl; or R5 and R6 together with the carbon atoms to which they are attached form a 5-6 membered heterocyclic ring comprising having 1-2 heteroatoms selected from N, O and S. 2. The method according to claim 1, wherein the EML4-ALK+ mediated non-small cell lung cancer is resistant to crizotinib. 3. The method of claim 1, wherein R1 in Formula (I) is chloro. 4. The method of claim 1, wherein R4 in Formula (I) is isopropoxy. 5. The method of claim 1, wherein R5 and R6 together with the carbon atoms to which they are attached form —CH2—NR8—C(O)—, wherein R8 is hydrogen or piperidinyl, optionally substituted with C1-6 alkyl. 6. The method of claim 1, wherein said compound of Formula (I) is selected from the group: 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-2-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; (S)-5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-2-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; (R)-5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-2-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-3-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; and 6-{5-Chloro-4-[2-(propane-2-sulfonyl)-phenylamino]-pyrimidin-2-ylamino}-5-isopropoxy-2-(1-methyl-piperidin-4-yl)-2,3-dihydro-isoindol-1-one; or a pharmaceutically acceptable salt thereof. 7. The method of claim 6, wherein said compound is 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine. 8. The method of claim 6, wherein said compound is 6-{5-Chloro-4-[2-(propane-2-sulfonyl)-phenylamino]-pyrimidin-2-ylamino}-5-isopropoxy-2-(1-methyl-piperidin-4-yl)-2,3-dihydro-isoindol-1-one. 9. The method of claim 1, wherein said subject is a human or animal subject.